For its proprietary human Neurons-as-a-Sensor NeuroFluidics platform
16 July 2026, Singapore – NETRI, a TechBio company combining human neuron-based technology and AI-powered analytics to improve drug development, has been named the winner of the 2026 Amgen x NSG BioLabs Golden Ticket in Singapore. The award is part of a joint programme by Amgen, a leader in biologic medicines, and NSG BioLabs, Singapore’s leading provider of biotechnology co-working laboratories and offices.
Now in its fifth year, the Golden Ticket programme supports high-potential biotechnology startups by providing access to world-class infrastructure, expert mentorship and strategic resources that help accelerate innovation and strengthen pathways from discovery to real-world impact. As this year’s recipient, NETRI will receive a one-year residency at NSG BioLabs, including access to certified BSL-2 laboratory facilities, as well as networking opportunities through Amgen’s ecosystem of scientific and business leaders.
NETRI was selected following an interactive pitch session reviewed by Amgen and NSG’s scientific committee. The company impressed judges with its innovative approach to one of drug development’s most enduring challenges: predicting whether potential therapies will be safe and effective before they enter clinical trials. Its proprietary human neuron-based neurofluidics platform combines New Approach Methodologies (NAMs) technology with AI-powered analytics to deliver earlier, more predictive insights, helping researchers make faster, better-informed decisions while reducing reliance on animal testing. Together, these strengths distinguished NETRI as the 2026 Golden Ticket winner.
